Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Hexatronic in conjunction with the acquisition of Opternus GmbH
Mandate

Vinge advises Hexatronic in conjunction with the acquisition of Opternus GmbH

October 25, 2018 M&A

Vinge has advised Hexatronic Group AB (publ), listed on Nasdaq Stockholm mid‑cap, in connection with the acquisition of the entire share capital in the German fibre optic company Opternus GmbH.

Opternus is the market leader within sales and service of fibre welds and measurement equipment on the fast growing German market for fibre optic equipment. The purchase price amounts to MEUR 10 on a cash and debt free basis as well as an earnout of a maximum of MEUR 2.7. The purchase price is paid with MEUR 9 in cash and MEUR 1 as newly issued shares in Hexatronic. Closing, which is subject to customary conditions, is anticipated shortly.

Vinge’s team primarily consisted of responsible partner Anders Strid, Wibeke Sorling and corporate assistant Camilla Andersson. In addition, ALP Rechtsanwälte through Dr. Sven Oksaar acted as local counsel.
 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025